Perfuse Therapeutics, Inc. is a seed stage biotechnology company focusing on improving retinal perfusion with a novel mechanism in the context of several retinal diseases including glaucoma, non-proliferative diabetic retinopathy, and intermediate age-related macular degeneration.  The company was founded by OrbiMed Advisors and is supported by a syndicate of investors including Camden Partners, Lilly Asia Ventures, and Wu Capital.